

# Tumor Suppressor Protein Pdc4 Inhibits Translation of p53 mRNA<sup>\*[S]</sup>

Received for publication, June 7, 2011, and in revised form, October 18, 2011. Published, JBC Papers in Press, October 27, 2011, DOI 10.1074/jbc.M111.269456

Lena Wedeken<sup>1</sup>, Priyanka Singh<sup>1</sup>, and Karl-Heinz Klempnauer<sup>2</sup>

From the Institut für Biochemie, Westfälische-Wilhelms-Universität Münster, D-48149 Münster, Germany

**Background:** Pdc4 is a tumor suppressor involved in translational regulation.

**Results:** Pdc4 interacts with p53 mRNA and inhibits its translation via the 5'-UTR. Under stress conditions, the expression of Pdc4 decreases.

**Conclusion:** Translation of p53 mRNA is suppressed by Pdc4 under normal growth conditions.

**Significance:** Pdc4 is a new translational regulator of p53.

The tumor suppressor protein Pdc4 is thought to suppress translation of mRNAs containing structured 5'-UTRs by interacting with translation initiation factor eIF4A and inhibiting its helicase activity. However, natural target mRNAs regulated by Pdc4 so far are mostly unknown. Here, we identified p53 mRNA as a translational target of Pdc4. We found that Pdc4 is associated with p53 mRNA and suppresses its translation. The inhibitory effect of Pdc4 on the translation of p53 mRNA depends on the ability of Pdc4 to interact with eIF4A and is mediated by the 5'-UTR of p53 mRNA, which is able to form a stable stem-loop structure. We show that treatment of cells with DNA-damaging agents decreases the expression of Pdc4. This suggests that translational suppression by Pdc4 plays a role in maintaining a low level of p53 in unstressed cells and that this suppression is abrogated due to low levels of Pdc4 after DNA damage. Overall, our work demonstrates for the first time that Pdc4 is directly involved in translational suppression of a natural mRNA with a 5'-structured UTR and provides novel insight into the translational control of p53 expression.

The tumor suppressor protein Pdc4 (programmed cell death 4) is a multifunctional nuclear-cytoplasmic shuttling and RNA-binding protein that has been implicated in the development of a broad spectrum of human tumors. Pdc4 is very highly conserved among vertebrates, with homologs being found also in evolutionarily divergent species, such as insects (e.g. *Drosophila melanogaster*), sponges (e.g. *Suberites domuncula*), and plants (Pfam Database). Pdc4 was originally identified as a gene whose expression is increased during apoptosis (1) and subsequently identified as a tumor suppressor. Initial work showed that Pdc4 is able to suppress tumor development in an *in vitro* mouse keratinocyte model of tumor promotion

(2). Further work showed that decreased expression of Pdc4 is associated with a large spectrum of tumors, including tumors of the lung, colon, liver, and breast (3–6). The decrease in Pdc4 expression in many cases has been ascribed to the expression of microRNA miR-21, whose overexpression in certain cancer cells down-regulates Pdc4 expression (7, 8). Pdc4 is also regulated at the protein level. For example, it has been shown that p70<sup>S6K</sup> kinase-mediated phosphorylation of Pdc4 triggers the ubiquitinylation of Pdc4 by the E3 ubiquitin ligase complex SCF<sup>BTRCP</sup> and its subsequent degradation (9). Recent work has suggested that down-regulation of Pdc4 expression might contribute to tumor development in several ways. siRNA-mediated knockdown of Pdc4 in breast cancer cells has been shown to increase the mobility and metastatic potential of tumor cells (7, 10). This is in line with the observation that Pdc4 suppresses AP-1-responsive promoters by inhibiting the activity of the transcription factor c-Jun (11, 12) and the fact that many of the AP-1 target genes are involved in cell motility and tumor cell invasion. In addition, accumulating evidence suggests that down-regulation of Pdc4 might also contribute to tumor development by disturbing the cellular DNA damage response (13, 14).

A substantial body of evidence has suggested that Pdc4 modulates the expression of other genes on two levels. Pdc4 affects transcription of certain genes by inhibiting the activities of specific transcription factors, such as c-Jun (11, 12), Sp1 (10), and p53 (13). In addition, Pdc4 is thought to act as a suppressor of translation. Pdc4 interacts with and inhibits the eukaryotic translation initiation factor eIF4A, whose RNA helicase activity is required for the unwinding of mRNA secondary structures present in 5'-UTRs of certain mRNAs (15, 16). Pdc4 harbors two so-called MA-3 domains, which mediate the binding of Pdc4 to eIF4A (15, 16). The structure of the MA-3 domains and the complex formation with eIF4A have been analyzed in detail by NMR spectroscopy and x-ray crystallography (17–22). Together with biochemical evidence, this has led to a model in which binding of Pdc4 to eIF4A inhibits the helicase activity of eIF4A (15, 16), resulting in the suppression of the cap-dependent translation of mRNAs with 5'-structured UTRs. However, as yet, physiological translational target mRNAs for Pdc4 have not been unambiguously identified to validate this mechanism of translational suppression by Pdc4.

\* This work was supported in part by grants from the Deutsche Krebshilfe, the Wilhelm-Sander-Stiftung, and the Deutsche Forschungsgemeinschaft.

[S] The on-line version of this article (available at <http://www.jbc.org>) contains supplemental "Experimental Procedures" and Figs. 1–3.

<sup>1</sup> Supported by fellowships from the Graduate School of Chemistry, University of Münster.

<sup>2</sup> To whom correspondence should be addressed: Inst. für Biochemie, Westfälische-Wilhelms-Universität Münster, Wilhelm-Klemm-Str. 2, D-48149 Münster, Germany. Tel.: 49-251-83-33203; Fax: 49-251-83-33206; E-mail: klempna@uni-muenster.de.

## Translational Regulation of p53 by Pdc4

Here, we demonstrate that the tumor suppressor p53 mRNA is a physiological target of Pdc4. We show that Pdc4 is associated with p53 mRNA and suppresses its translation. The inhibitory effect of Pdc4 depends on the ability to interact with eIF4A and is mediated by the 5'-UTR of p53 mRNA, which is known to form a stable stem-loop structure. We also show that Pdc4 expression is diminished upon treatment with DNA-damaging agents. In summary, our work demonstrates for the first time that Pdc4 is directly involved in translational suppression of a natural mRNA with a 5'-structured UTR. Furthermore, our work implicates Pdc4 in restraining p53 expression in the absence of DNA damage, identifying it as a hitherto unknown regulator of the basal p53 expression level.

### EXPERIMENTAL PROCEDURES

**Cells**—Cell lines were obtained from American Type Culture Collection. HeLa cell clones stably expressing Pdc4-specific shRNAs have been described previously (13).

**Expression Vectors**—The p53 expression vector containing p53 UTRs and luciferase expression vectors containing p53 or Mdm2 UTRs were obtained from L. Xiong and L. Wu (23). The expression vector encoding GFP-p53 has been described (24). The human Pdc4 expression vector pcDNA4-hPdc4 (encoding full-length human Pdc4) has been described (25). pcDNA4-hPdc4-mut4 encodes a mutant of human Pdc4 in which Glu-249, Asp-253, Asp-414, and Asp-418 were changed to Ala. The  $\beta$ -galactosidase expression vector pCVM $\beta$  was obtained from Invitrogen.

**Antibodies**—Pdc4 was visualized with rabbit antiserum raised against the N terminus of human Pdc4 (13). Monoclonal antibodies against p53 (DO-1) and  $\beta$ -actin (AC-15) were obtained from Sigma-Aldrich.

**RNA Isolation**—Total cellular RNA was isolated with the NucleoSpin<sup>®</sup> RNA II kit (Macherey-Nagel) following the instructions of the manufacturer. To isolate nuclear and cytoplasmic RNAs, cells were lysed in hypotonic buffer containing 10 mM Hepes (pH 7.5), 5 mM KCl, 2 mM MgCl<sub>2</sub>, 0.5% Nonidet P-40, and 1 mM PMSF supplemented with RNase inhibitor RNaseOUT<sup>™</sup> (Invitrogen) and a protease inhibitor mixture (consisting of pepstatin A, leupeptin hemisulfate, and aprotinin) and pelleted at 14,000 rpm for 15 min at 4°C. RNA was isolated from the supernatant (cytoplasmic fraction) and the pellet (nuclear fraction) by TRIzol (Invitrogen) extraction and isopropyl alcohol precipitation.


**cDNA Synthesis and Real-time PCR**—First-strand cDNA synthesis was performed with a cDNA kit (Fermentas). The cDNAs were analyzed by quantitative real-time PCR with the following primers: p53, 5'-CAGGTAGCTGCTGGGCTC-3' and 5'-GCTCGACGCTAGGATCTGAC-3'; Pdc4, 5'-TGTAAACCCTGCAGATCCTGATAA-3' and 5'-TGGAGGATGCTGAAATCCAA-3'; Mdm2, 5'-AAGCCTGGCTCTGTGTGTA-3' and 5'-CTGATCCAACCAATCACCTG-3';  $\beta$ -actin, 5'-CGTCCACCGCAAATGCTT-3' and 5'-GTTTTCTGCGCAAGTTAGGT-3'; luciferase, 5'-TTTGTGCCAGAGTCCTTCGAT-3' and 5'-GAGAATCTCACGCAGGCAGTT-3'; and  $\beta$ -galactosidase, 5'-CTGGCTGGAGTGCGATCTTC-3' and 5'-GGCGGATTGACCGTAATGG-3'. Real-time PCR was performed using Power SYBR<sup>®</sup> Green PCR

Master Mix (Applied Biosystems) and a StepOnePlus real-time PCR machine (Applied Biosystems). p53, Pdc4, and luciferase mRNAs in knockdown and transfection experiments were quantitated by the  $\Delta\Delta C_T$  method. First,  $\Delta C_T$  values for p53 (or Pdc4) RNA were calculated by subtracting the  $C_T$  values obtained for this mRNA from those obtained for  $\beta$ -actin mRNA, thereby normalizing the amount of p53 and Pdc4 mRNAs with respect to that of a housekeeping gene. Similarly, in transfection experiments, the amount of luciferase RNA was normalized with respect to the  $\beta$ -galactosidase RNA.  $\Delta\Delta C_T$  values were calculated by subtracting the  $\Delta C_T$  values of the knockdown cells (or the Pdc4-transfected cells) from the  $\Delta C_T$  values of the control siRNA cells (or the control transfected cells). The normalized amounts were then calculated as  $2^{-\Delta\Delta C_T}$ . For RNA immunoprecipitation (RIP)<sup>3</sup> experiments,  $\Delta C_{T(RIP)}$  values were calculated by subtracting the  $\Delta C_T$  values of input samples (after correcting them for dilution factors) from those of RIP samples. RNA amounts in RIP samples were then calculated as a percentage of input samples as  $100 \times 2^{-\Delta C_{T(RIP)}}$ . For sucrose gradient experiments,  $C_T$  values obtained for p53 and Mdm2 mRNAs in pooled gradient fractions 4–7 and 8–11 were subtracted from the  $C_T$  values of pooled fractions 1–3, thereby normalizing to the amounts in the nonribosomal fractions. The obtained  $\Delta C_T$  values were then used to calculate the relative amounts of these RNAs in fractions 4–7 and 8–11 as  $2^{-\Delta C_T}$ .

**Sucrose Density Gradients**—Density gradient centrifugation and visualization of ribosomal RNAs were performed as described previously (25) except that the gradients were centrifuged in an SW 50.1 rotor (Beckman) at 45,000 rpm for 1 h at 4°C. For RNA analysis by real-time PCR, gradient fractions were treated with proteinase K, and RNA was isolated by TRIzol extraction and isopropyl alcohol precipitation. cDNA synthesis and real-time PCR were performed as described above.

**RIP**—HepG2 cells were fixed with 0.5% formaldehyde in phosphate-buffered saline for 5 min at room temperature, followed by addition of 125 mM glycine for 5 min. Cells were lysed in hypotonic buffer. 10% of the supernatant (cytoplasmic fraction) was saved as the input sample, and the remaining material was used for immunoprecipitation for 2 h at 4°C with rabbit antiserum raised against the N terminus of human Pdc4 (13). The antibodies were prebound to protein A-Sepharose, which had been blocked with BSA and tRNA for 2 h at 4°C, and washed several times with egg lysis buffer (50 mM Hepes (pH 7.5), 120 mM NaCl, 20 mM NaF, 1 mM EDTA, 6 mM EGTA, 15 mM sodium PP<sub>i</sub>, 0.5% Nonidet P-40, and 1 mM PMSF supplemented with protease inhibitor mixture and RNase inhibitor). The immunoprecipitates were washed several times with egg lysis buffer. After elution from the beads with 1% SDS, the samples were reverse cross-linked for 4 h at 65°C and further treated with RNase-free DNase I for 15 min at room temperature, followed by proteinase K treatment for 1 h at 37°C. RNA was purified by TRIzol extraction and isopropyl alcohol precipitation. cDNA synthesis and real-time PCR were performed as described above.

<sup>3</sup>The abbreviation used is: RIP, RNA immunoprecipitation.



**FIGURE 1. siRNA-mediated knockdown of Pcdcd4 up-regulates p53 expression.** *A*, Western blot analysis of HeLa cells (WT) and two stable Pcdcd4 knockdown clones (K11 and K12). The Western blots were developed with antisera against Pcdcd4, p53, and  $\beta$ -actin as indicated. Cells were grown in normal growth medium or in medium supplemented with 10  $\mu$ M proteasome inhibitor MG132 for 4 h before harvesting. *B*, HeLa cells were transiently transfected with control siRNA or with two different Pcdcd4-specific siRNAs. Cell extracts were analyzed by Western blotting for the expression of Pcdcd4, p53, and  $\beta$ -actin. *C*, HepG2 cells were transiently transfected with control siRNA or with two different Pcdcd4-specific siRNAs. Cells were treated with or without the proteasome inhibitor MG132 as indicated, and cell extracts were analyzed by Western blotting for the expression of Pcdcd4, p53, and  $\beta$ -actin. *D*, total RNA isolated from siRNA-transfected HepG2 cells was analyzed by quantitative real-time PCR for the expression of p53 (black bars) and Pcdcd4 (white bars) mRNAs. *E*, the nuclear-cytoplasmic distribution of p53 mRNA in HepG2 cells transfected with control or Pcdcd4-specific siRNAs was analyzed by real-time PCR.

**Transfections and Reporter Gene Assays**—Transfections in the QT6 quail fibroblast line using the calcium phosphate coprecipitation method and luciferase and  $\beta$ -galactosidase reporter assays were performed as described previously (13).

**RNA Interference**—siRNA duplexes were obtained from Eurogentec (Liege, Belgium). The Pcdcd4 siRNA target sequences were 5'-GUGUUGGCAGUAUCCUAG-3' (Pcdcd4\_603), 5'-GGAGAACUGUGUUUAUGAA-3' (Pcdcd4\_682), and 5'-GCAUGGAUACUAAUGAA-3' (Pcdcd4\_772). siRNA directed against *Renilla* luciferase (target sequence, 5'-AAACAUGCAGAAAUGCUG-3') was used as negative control. Approximately  $2.5 \times 10^5$  cells were plated the day before transfection in 6-cm plates and received 1.5 ml of fresh growth medium prior to transfection. siRNA was transfected using Metafectene<sup>TM</sup> Pro (Biontex Laboratories GmbH) or HiPerFect (Qiagen), according to the manufacturers' protocols. Cells were harvested 48 h later and processed further for Western blotting or RNA analysis as appropriate.


## RESULTS

**Knockdown of Pcdcd4 Increases p53 Expression Levels**—We have previously shown that siRNA-mediated knockdown of Pcdcd4 stimulates the activity of p53, leading to increased transcription of certain p53 target genes, such as p21<sup>Waf1/Cip1</sup> (13). During this work, we noted that the knockdown of Pcdcd4 resulted in a slight but reproducible increase in the amount of p53, suggesting that Pcdcd4 influences not only the activity of

p53 but also its expression. Fig. 1*A* compares the p53 expression levels of two clones of HeLa cells stably expressing Pcdcd4-specific shRNA and of a control clone. The expression of Pcdcd4 was substantially decreased in the knockdown clones, as expected, whereas the amount of p53 was increased in these clones. Because regulatory mechanisms that affect the expression of p53 in many cases alter the stability of p53 (26–28), we wondered whether the increased level of p53 after Pcdcd4 knockdown was due to stabilization of p53. To address this, we compared the p53 protein levels between Pcdcd4 knockdown and control clones after treating the cells with the proteasome inhibitor MG132. We reasoned that if the knockdown of Pcdcd4 increased the half-life of p53, treatment with the proteasome inhibitor would override such a stabilizing effect. However, as shown in Fig. 1*A* (lower panels), this appeared not to be the case, as there was still a significant difference in the amount of p53 between the knockdown and control clones.

In addition to using the stable HeLa Pcdcd4 knockdown clones, we performed transient transfections of HeLa cells with two different Pcdcd4-specific siRNAs and with control siRNA. Fig. 1*B* shows that the expression of p53 was also elevated after transient knockdown of Pcdcd4, indicating that the effects observed in the stable knockdown clones were not due to clonal variation. To demonstrate that the increased expression of p53 after Pcdcd4 knockdown was not restricted to HeLa cells, we also

## Translational Regulation of p53 by Pdc4




**FIGURE 2. Pdc4 is associated with p53 mRNA *in vivo*.** Cytoplasmic extracts of HepG2 cells were subjected to RIP with Pdc4-specific (*black bars*) or control (*white bars*) antibodies. *Bars* indicate the relative amounts of p53, Pdc4, and  $\beta$ -actin RNAs in the immunoprecipitates as determined by quantitative real-time PCR.

analyzed p53 expression in HepG2 cells (which express wild-type p53) after transient transfection with Pdc4-specific and control siRNAs. As shown in Fig. 1C, the p53 levels were also elevated in the cells transfected with Pdc4-specific siRNA. This indicated that the increase in p53 expression after Pdc4 knockdown was not a cell line-specific effect. Using HepG2 cells, we also confirmed that treatment with the proteasome inhibitor MG132 does not override the effect of the Pdc4 knockdown. On the basis of these results, we concluded that Pdc4 knockdown elevates the p53 expression level and that this is not due to increased stability of p53. To demonstrate that the stability of p53 was not affected by the Pdc4 knockdown, we also compared the half-life of p53 in Pdc4 control and knockdown cells ([supplemental Fig. 1](#)). These experiments did not reveal any significant differences in the stability of p53 after knockdown of Pdc4.

To further understand how Pdc4 affects the expression of p53, we asked whether Pdc4 knockdown affects the level of p53 mRNA or its nuclear-cytoplasmic distribution. However, as shown in Fig. 1 (*D* and *E*), the reduced Pdc4 expression did not significantly affect the amount of p53 mRNA or its distribution between the cytoplasm and nucleus. This demonstrated that Pdc4 does not influence the transcription, stability, or nuclear export of p53 mRNA but rather suggested that Pdc4 affects the translation of p53 mRNA.

**Pdc4 Binds to p53 mRNA and Suppresses Its Translation—**To confirm that Pdc4 affects the translation of p53 mRNA, we first asked whether Pdc4 is associated with p53 mRNA *in vivo*. Previously, we have shown that Pdc4 co-sediments with ribosomal preinitiation complexes in sucrose density gradients (25), suggesting that Pdc4 directly targets certain mRNAs. To investigate whether Pdc4 is associated with p53 mRNA, we performed RIP experiments. We prepared cytoplasmic extracts from formaldehyde-fixed HepG2 cells and immunoprecipitated them with Pdc4-specific or control antiserum. RNA isolated from the immunoprecipitates was then analyzed by real-time PCR using gene-specific primers. Fig. 2 shows that p53 mRNA was enriched in the Pdc4-specific immunoprecipitate




**FIGURE 3. Knockdown of Pdc4 increases the polysomal association of p53 mRNA.** Cytoplasmic extracts of HepG2 cells transiently transfected with control or Pdc4-specific siRNA were fractionated by sedimentation through 10–50% sucrose density gradients. Aliquots of the gradient fractions were analyzed by agarose gel electrophoresis to visualize the distribution of 18 S and 28 S ribosomal RNAs (*upper*). Subsequently, fractions 1–3, 4–7, and 8–11 were pooled as nonribosomal, monoribosomal, and polyribosomal fractions as indicated. Total RNA isolated from these pools was then analyzed by quantitative real-time PCR for p53 (*black bars*) and Mdm2 (*white bars*) mRNAs. The *bar height* reflects the amounts of p53 and Mdm2 RNAs normalized to the amount of the corresponding RNA in the nonribosomal pool.

compared with the control precipitate. By contrast, Pdc4 and Mdm2 mRNAs, which were analyzed as controls, were not enriched in the Pdc4-specific immunoprecipitate. This demonstrated that Pdc4 is associated with p53 mRNA, consistent with the notion that Pdc4 inhibits the translation of p53 mRNA.

To further explore the idea that p53 mRNA is a translational target of Pdc4, we transfected HepG2 cells with Pdc4-specific or control siRNAs and then fractionated cytoplasmic extracts of these cells by sucrose density gradient centrifugation. RNA was isolated from pooled nonribosomal, monoribosomal, and polyribosomal fractions, and the distribution of p53 mRNA between these fractions was determined by quantitative real-time PCR. This allowed us to determine whether the amount of p53 mRNA engaged in translation (*i.e.* associated with monoribosomes and polyribosomes) was affected by the Pdc4 knockdown. We also analyzed the distribution of p53 mRNA as a control. Fig. 3 shows that the relative amount of p53 mRNA in the polyribosomal fractions increased upon knockdown of Pdc4, whereas the distribution of Mdm2 mRNA remained unaffected. This clearly demonstrated that knockdown of Pdc4 results in increased translation of p53 mRNA. We therefore concluded that Pdc4 associates with p53 mRNA and suppresses its translation.


**Suppression of p53 Expression by Pdc4 Is Mediated by the 5'-UTR of p53 mRNA—**To address the mechanism of translational suppression of p53 mRNA by Pdc4, we first examined the effect of Pdc4 on the amount of p53 generated from a cotransfected p53 expression vector. Fig. 4A shows that Pdc4 suppressed the expression of p53 from an expression vector containing the authentic p53 5'- and 3'-UTRs. This effect of



**FIGURE 4. Translational suppression by Pcdcd4 is mediated by the UTRs of p53 mRNA.** *A*, QT6 fibroblasts were transfected with increasing amounts of expression vector for human Pcdcd4 and with plasmids containing the p53 coding region and the authentic p53 UTRs or containing the coding region for p53 fused to GFP but lacking the p53 UTRs. Cells were additionally transfected with the  $\beta$ -galactosidase expression vector pCMV $\beta$  to normalize for transfection efficiencies.  $\beta$ -Galactosidase-normalized amounts of cell extracts prepared 24 h after transfection were then analyzed by Western blotting with antibodies against p53 and Pcdcd4. *B*, total RNA of cells transfected as described for *A* was analyzed by real-time PCR for the expression of p53 mRNA. *C* and *D*, QT6 fibroblasts were transfected with increasing amounts of expression vector for human Pcdcd4 and plasmids containing the luciferase coding region and both p53 or Mdm2 UTRs. Cells were additionally transfected with the  $\beta$ -galactosidase expression vector pCMV $\beta$  to normalize for transfection efficiencies. The bars in the left panels indicate the  $\beta$ -galactosidase-normalized luciferase activities of cell extracts prepared 24 h after transfection. The right panels show real-time PCR analyses of total RNA isolated from cells transfected with the same combinations of plasmids (using only the highest amount of Pcdcd4 expression vector). The bars indicate the amounts of luciferase mRNA under the different conditions.

Pcdcd4 was not due to inhibition of the amount of p53 mRNA generated from this vector, as shown by real-time PCR (Fig. 4*B*). Pcdcd4 had virtually no effect on the amount of p53 when an expression vector for GFP-tagged p53 lacking the authentic p53 UTRs was used, suggesting that the inhibitory effect of Pcdcd4 is mediated by the UTRs of p53 mRNA. To further explore this possibility, we used a luciferase expression vector in which the luciferase coding region was flanked by the p53 UTRs. Fig. 4*C* shows that the luciferase expression was suppressed by Pcdcd4. By contrast, the luciferase activity generated by transfection of a similar expression vector containing the Mdm2 UTRs was not affected by Pcdcd4 (Fig. 4*D*), confirming the specificity of the Pcdcd4-mediated suppression. Real-time PCR analyses again confirmed that Pcdcd4 did not affect the luciferase mRNA levels in both cases, consistent with the notion that Pcdcd4 suppresses the translation of the luciferase RNA containing the p53 UTRs.


It has been shown previously that the p53 5'-UTR has the potential to form a stable hairpin structure (29). Disruption of such hairpins during translation initiation is thought to require the helicase activity of eIF4A (30). Because Pcdcd4 is known to interact with eIF4A and to inhibit its helicase activity (15), we were interested to know whether the p53 5'-UTR is the target for the suppressive effect of Pcdcd4. To investigate the role of the p53 5'-UTR in Pcdcd4-dependent translational suppression, we used a luciferase construct containing only the p53 5'-UTR. Fig. 5*A* shows that the luciferase expression of this construct was



**FIGURE 5. Translational suppression by Pcdcd4 is mediated by the p53 5'-UTR and is dependent on the ability of Pcdcd4 to interact with eIF4A.** *A*, QT6 fibroblasts were transfected with increasing amounts of expression vector for human Pcdcd4 and plasmids containing the luciferase coding region and the p53 5'-UTR. Cells were additionally transfected with the  $\beta$ -galactosidase expression vector pCMV $\beta$  to normalize the transfection efficiencies. The bars show the  $\beta$ -galactosidase-normalized luciferase activities of cell extracts prepared 24 h after transfection. *B*, cells were transfected and analyzed as described for *A* except that equal amounts of expression vector for WT human Pcdcd4 or a Pcdcd4 mutant not able to interact with eIF4A (Pcdcd4-mut4) were transfected. Comparable expression of both Pcdcd4 proteins was confirmed by the Western blot shown at the bottom.

suppressed by Pcdcd4 as efficiently as the expression of the construct containing both UTRs shown in Fig. 4*C*. To further examine whether the suppressive effect of Pcdcd4 is dependent

## Translational Regulation of p53 by Pdc4



**FIGURE 6. Treatment with DNA-damaging agents down-regulates Pdc4 expression.** *A*, HepG2 cells were irradiated with  $\sim 100$  J/m<sup>2</sup> UV light or treated with 15  $\mu$ g/ml etoposide, followed by further incubation for different times and Western blot analysis of total cellular protein extracts with antibodies against Pdc4 and  $\beta$ -actin. *B*, HepG2 cells were treated and incubated for the indicated times as described for *A*, followed by Western blot analysis with antibodies against Pdc4, p53, and  $\beta$ -actin. *C* and *D*, schematic models explaining the function of Pdc4 in the suppression of p53 mRNA translation under normal growth conditions (*C*) and after induction of DNA damage (*D*). 4A, 4E, and 4G refer to the translation initiation factors eIF4A, eIF4E, and eIF4G, respectively.

on the ability of Pdc4 to interact with eIF4A, we used a mutant of Pdc4 (referred to as Pdc4-mut4) that carries several amino acid substitutions of residues known to interact with eIF4A and is thus unable to interact with eIF4A. Fig. 5*B* shows that the Pdc4 mutant failed to suppress the luciferase expression of the construct containing the p53 5'-UTR, indicating that Pdc4 suppresses translation by interfering with the function of eIF4A. We also investigated the effect of Pdc4 on truncated versions of the p53 5'-UTR to see if the ability of Pdc4 to inhibit translation correlates with the secondary structure-forming potential of the UTRs. The experiments shown in [supplemental Fig. 2](#) demonstrate that this was the case, suggesting that the ability of Pdc4 to suppress translation is dependent on the secondary structure-forming potential of the 5'-UTR. The p53 5'-UTR also contains an internal ribosomal entry site (31, 32). We generated a bicistronic reporter plasmid containing the p53 internal ribosomal entry site to see if Pdc4 affects its activity; however, we found that Pdc4 did not affect internal ribosomal entry site-dependent translation (data not shown). This further supports the notion that Pdc4 affects the cap-dependent translation of p53 mRNA via binding to eIF4A.

**Treatment with DNA-damaging Agents Down-regulates Pdc4 Expression**—Our data suggest a novel role of Pdc4 in reducing the level of p53 expression in cells grown under normal growth conditions. We therefore wondered if and how the suppressive effect exerted by Pdc4 is relieved upon DNA damage, when higher levels of p53 are required. To address this, we irradiated HepG2 cells with UV light. When the Pdc4 expres-

sion level was analyzed by Western blotting, it was apparent that the amount of Pdc4 was significantly decreased following UV irradiation, whereas the level of p53 was increased (Fig. 6). A similar observation was made with another cell line, HCT116 ([supplemental Fig. 3](#)), and when HepG2 cells were treated with the topoisomerase II inhibitor etoposide. These observations suggested that the suppressive effect of Pdc4 is diminished under DNA-damaging conditions. Taken together, our data suggest the models depicted in Fig. 6 (*C* and *D*). In cells grown under normal growth conditions, Pdc4 appears to suppress the translation of p53 mRNA, thereby contributing to the low steady-state level of p53. In cells stressed with DNA-damaging agents, Pdc4 levels are reduced, abrogating the Pdc4-dependent suppression of translation and permitting increased translation of p53 mRNA.

## DISCUSSION

The p53 protein is a key regulator of cell survival and death, and its function is tightly controlled at multiple levels. In particular, regulation of proteasome-mediated degradation of p53 by the E3 ubiquitin ligase Mdm2 and of post-translational modification has been identified as a key regulatory mechanism to control the half-life and activity of p53 in response to DNA damage (26–28). There is strong evidence that p53 protein levels are also regulated at the level of translation of p53 mRNA (33). The p53 5'-UTR is able to form a stable stem-loop that is expected to affect the initiation of translation of p53 (29). Furthermore, an internal ribosomal entry site whose activity is

stimulated by DNA damage has been mapped in the 5'-UTR of p53 mRNA (31, 32). Several proteins bind the p53 UTRs. For example, it was shown that the binding of the ribosomal protein RPL26 to the p53 5'-UTR increases the translation of p53 mRNA under normal conditions and after DNA damage (34, 35). The p53 3'-UTR has also been implicated in translational regulation of p53 mRNA, mediated by the RNA-binding proteins HuR (36) and Wig-1 (37). Recently, a novel regulatory mechanism that involves complementary nucleotide sequences in the 5'- and 3'-UTRs has been described and implicated in translational regulation mediated by RPL26 (38). Finally, the p53 3'-UTR is targeted by several microRNAs, which affect the stability or translation of p53 mRNA (39, 40).

We have identified Pcd4 as a novel regulator of p53 mRNA translation. siRNA-mediated silencing of Pcd4 expression caused an increase in the p53 protein level, which was not due to increased p53 protein stability or increased mRNA transcription. Rather, our data show that the amount of p53 mRNA associated with polysomes was increased after Pcd4 knock-down and that Pcd4 was associated with p53 mRNA *in vivo*. Taken together, these observations identify p53 mRNA as a physiological target of Pcd4 and implicate Pcd4 as a novel factor involved in translational regulation of p53 mRNA.

Because Pcd4 directly interacts with translation initiation factor eIF4A and inhibits the helicase activity of eIF4A (15, 16), Pcd4 was proposed to act as a translational suppressor of mRNAs containing structured 5'-UTRs whose disruption during translation initiation requires the helicase activity of eIF4A. Although this idea gained preliminary support from studies showing that translation of artificial RNA constructs harboring stable stem-loop structures at their 5'-ends was decreased when Pcd4 was overexpressed (15, 16), physiological mRNAs regulated by Pcd4 via such a mechanism of translational control are not known so far. We recently identified proto-oncogene *c-myc* mRNA as a translational target of Pcd4 and showed that Pcd4 suppresses translation of *c-myc* RNA independently of its 5'-UTR but via a responsive element located in the *c-myc* coding region (41). The work described here identifies p53 mRNA as a novel target of Pcd4 and clearly shows that Pcd4 suppresses the translation of p53 mRNA in an eIF4A-dependent manner via the p53 5'-UTR. Our work therefore demonstrates for the first time that Pcd4 is directly involved in translational suppression of a natural mRNA with a 5'-structured UTR.

Our work also provides new insight into the regulation of Pcd4 itself. We showed that Pcd4 protein levels decreased after treatment of cells with DNA-damaging agents, such as UV light or the topoisomerase inhibitor etoposide. This suggests a model in which Pcd4 serves to suppress p53 translation in the absence of DNA damage when p53 protein levels are low, whereas translational suppression by Pcd4 is abrogated due to the decrease in Pcd4 in the presence of DNA damage when p53 levels increase. Thus, Pcd4 appears to contribute to maintaining a low level of p53 expression that is crucial for the homeostasis of unstressed cells. Previously, we showed that Pcd4 also inhibits the activity of p53 by interfering with the CBP (cAMP-responsive element-binding protein-binding protein)-dependent acetylation of p53 (13). Thus, Pcd4 appar-

ently affects p53 by two different mechanisms resulting in the suppression of the synthesis and activity of p53. The existence of a dual mechanism by which Pcd4 controls p53 underlines the importance of the suppressive effects exerted by Pcd4 on p53.

What are the consequences of p53 inhibition by Pcd4? As pointed out above, p53 has well established roles in controlling the balance between death, senescence, and survival of DNA-damaged cells. By disturbing this balance, deregulation of Pcd4 could result in decreased susceptibility to apoptosis and, therefore, in the survival of cells containing damaged DNA. This is in line with our previous observation that the knock-down of Pcd4 suppresses apoptosis in UV-irradiated cells (13) in a p53-dependent manner (14). The survival of such cells might ultimately contribute to the development of tumors. Beyond its role in the response to acute genotoxic stress, p53 has been implicated in numerous aspects of cellular physiology in response to different kinds of stress as well as in unstressed cells. There is clear evidence for a role of p53 in the regulation of the cellular energy metabolism and antioxidant function, autophagy, invasion and motility, angiogenesis, differentiation, necrosis, and inflammation (42–46). By affecting the translation and activity of p53, Pcd4 is likely to exert pleiotropic effects on these biological processes and thereby influence the cellular homeostasis. The identification of p53 mRNA as a translational target of Pcd4 therefore provides new perspectives for future studies on the function of Pcd4.

---

*Acknowledgments*—We thank L. Xiong and J. Wu for providing plasmids and L. Waters and M. Carr (University of Leicester) and the members of our group for discussions.

---

## REFERENCES

- Shibahara, K., Asano, M., Ishida, Y., Aoki, T., Koike, T., and Honjo, T. (1995) *Gene* **166**, 297–301
- Cmarik, J. L., Min, H., Hegamyer, G., Zhan, S., Kulesz-Martin, M., Yoshinaga, H., Matsuhashi, S., and Colburn, N. H. (1999) *Proc. Natl. Acad. Sci. U.S.A.* **96**, 14037–14042
- Chen, Y., Knösel, T., Kristiansen, G., Pietas, A., Garber, M. E., Matsuhashi, S., Ozaki, I., and Petersen, I. (2003) *J. Pathol.* **200**, 640–646
- Afonja, O., Juste, D., Das, S., Matsuhashi, S., and Samuels, H. H. (2004) *Oncogene* **23**, 8135–8145
- Zhang, H., Ozaki, I., Mizuta, T., Hamajima, H., Yasutake, T., Eguchi, Y., Ideguchi, H., Yamamoto, K., and Matsuhashi, S. (2006) *Oncogene* **25**, 6101–6112
- Mudduluru, G., Medved, F., Grobholz, R., Jost, C., Gruber, A., Leupold, J. H., Post, S., Jansen, A., Colburn, N. H., and Allgayer, H. (2007) *Cancer* **110**, 1697–1707
- Asangani, I. A., Rasheed, S. A., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., and Allgayer, H. (2008) *Oncogene* **27**, 2128–2136
- Lu, Z., Liu, M., Stribinskis, V., Klinge, C. M., Ramos, K. S., Colburn, N. H., and Li, Y. (2008) *Oncogene* **27**, 4373–4379
- Dorrello, N. V., Peschiaroli, A., Guardavaccaro, D., Colburn, N. H., Sherman, N. E., and Pagano, M. (2006) *Science* **314**, 467–471
- Leupold, J. H., Yang, H. S., Colburn, N. H., Asangani, I., Post, S., and Allgayer, H. (2007) *Oncogene* **26**, 4550–4562
- Yang, H. S., Knies, J. L., Stark, C., and Colburn, N. H. (2003) *Oncogene* **22**, 3712–3720
- Bitomsky, N., Böhm, M., and Klemmner, K. H. (2004) *Oncogene* **23**, 7484–7493
- Bitomsky, N., Wethkamp, N., Marikkannu, R., and Klemmner, K. H.

## Translational Regulation of p53 by Pdc4

- (2008) *Oncogene* **27**, 4820–4829
14. Singh, P., Marikkannu, R., Bitomsky, N., and Klempnauer, K. H. (2009) *Oncogene* **28**, 3758–3764
  15. Yang, H. S., Jansen, A. P., Komar, A. A., Zheng, X., Merrick, W. C., Costes, S., Lockett, S. J., Sonenberg, N., and Colburn, N. H. (2003) *Mol. Cell Biol.* **23**, 26–37
  16. Yang, H. S., Cho, M. H., Zakowicz, H., Hegamyer, G., Sonenberg, N., and Colburn, N. H. (2004) *Mol. Cell Biol.* **24**, 3894–3906
  17. LaRonde-LeBlanc, N., Santhanam, A. N., Baker, A. R., Wlodawer, A., and Colburn, N. H. (2007) *Mol. Cell Biol.* **27**, 147–156
  18. Waters, L. C., Veverka, V., Böhm, M., Schmedt, T., Choong, P. T., Muskett, F. W., Klempnauer, K. H., and Carr, M. D. (2007) *Oncogene* **26**, 4941–4950
  19. Suzuki, C., Garces, R. G., Edmonds, K. A., Hiller, S., Hyberts, S. G., Marintchev, A., and Wagner, G. (2008) *Proc. Natl. Acad. Sci. U.S.A.* **105**, 3274–3279
  20. Chang, J. H., Cho, Y. H., Sohn, S. Y., Choi, J. M., Kim, A., Kim, Y. C., Jang, S. K., and Cho, Y. (2009) *Proc. Natl. Acad. Sci. U.S.A.* **106**, 3148–3153
  21. Loh, P. G., Yang, H. S., Walsh, M. A., Wang, Q., Wang, X., Cheng, Z., Liu, D., and Song, H. (2009) *EMBO J.* **28**, 274–285
  22. Waters, L. C., Strong, S. L., Ferlemann, E., Oka, O., Muskett, F. W., Veverka, V., Banerjee, S., Schmedt, T., Henry, A. J., Klempnauer, K. H., and Carr, M. D. (2011) *J. Biol. Chem.* **286**, 17270–17280
  23. Xiong, L., Kou, F., Yang, Y., and Wu, J. (2007) *J. Cell Biol.* **178**, 995–1007
  24. Wethkamp, N., and Klempnauer, K. H. (2009) *J. Biol. Chem.* **284**, 28783–28794
  25. Wedeken, L., Ohnheiser, J., Hirschi, B., Wethkamp, N., and Klempnauer, K. H. (2010) *Genes Cancer* **1**, 293–301
  26. Vousden, K. H., and Lu, X. (2002) *Nat. Rev. Cancer* **2**, 594–604
  27. Harris, S. L., and Levine, A. J. (2005) *Oncogene* **24**, 2899–2908
  28. Kruse, J. P., and Gu, W. (2009) *Cell* **137**, 609–622
  29. Mosner, J., Mummenbrauer, T., Bauer, C., Sczakiel, G., Grosse, F., and Deppert, W. (1995) *EMBO J.* **14**, 4442–4449
  30. Sonenberg, N., and Hinnebusch, A. G. (2009) *Cell* **136**, 731–745
  31. Ray, P. S., Grover, R., and Das, S. (2006) *EMBO Rep.* **7**, 404–410
  32. Yang, D. Q., Halaby, M. J., and Zhang, Y. (2006) *Oncogene* **25**, 4613–4619
  33. Vilborg, A., Wilhelm, M. T., and Wiman, K. G. (2010) *J. Mol. Med.* **88**, 645–652
  34. Takagi, M., Absalon, M. J., McLure, K. G., and Kastan, M. B. (2005) *Cell* **123**, 49–63
  35. Ofir-Rosenfeld, Y., Boggs, K., Michael, D., Kastan, M. B., and Oren, M. (2008) *Mol. Cell* **32**, 180–189
  36. Mazan-Mamczarz, K., Galbán, S., López de Silanes, I., Martindale, J. L., Atasoy, U., Keene, J. D., and Gorospe, M. (2003) *Proc. Natl. Acad. Sci. U.S.A.* **100**, 8354–8359
  37. Vilborg, A., Glahder, J. A., Wilhelm, M. T., Bersani, C., Corcoran, M., Mahmoudi, S., Rosenstierne, M., Grandér, D., Farnebo, M., Norrild, B., and Wiman, K. G. (2009) *Proc. Natl. Acad. Sci. U.S.A.* **106**, 15756–15761
  38. Chen, J., and Kastan, M. B. (2010) *Genes Dev.* **24**, 2146–2156
  39. Le, M. T., Teh, C., Shyh-Chang, N., Xie, H., Zhou, B., Korzh, V., Lodish, H. F., and Lim, B. (2009) *Genes Dev.* **23**, 862–876
  40. Zhang, Y., Gao, J. S., Tang, X., Tucker, L. D., Quesenberry, P., Rigoutsos, I., and Ramratnam, B. (2009) *FEBS Lett.* **583**, 3725–3730
  41. Singh, P., Wedeken, L., Waters, L. C., Carr, M. D., and Klempnauer, K. H. (2011) *Oncogene* 10.1038/onc.2011.202
  42. Bensaad, K., and Vousden, K. H. (2007) *Trends Cell Biol.* **17**, 286–291
  43. Vousden, K. H., and Lane, D. P. (2007) *Nat. Rev. Mol. Cell Biol.* **8**, 275–283
  44. Mathew, R., Karantza-Wadsworth, V., and White, E. (2007) *Nat. Rev. Cancer* **7**, 961–967
  45. Green, D. R., and Kroemer, G. (2009) *Nature* **458**, 1127–1130
  46. Vousden, K. H., and Ryan, K. M. (2009) *Nat. Rev. Cancer* **9**, 691–700